Literature DB >> 8473509

Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice.

T Hayek1, Y Ito, N Azrolan, R B Verdery, K Aalto-Setälä, A Walsh, J L Breslow.   

Abstract

In humans, diets high in saturated fat and cholesterol raise HDL-cholesterol (HDL-C) levels. To explore the mechanism, we have devised a mouse model that mimics the human situation. In this model, HuAITg and control mice were studied on low fat (9% cal)-low cholesterol (57 mg/1,000 kcal) (chow) and high fat (41% cal)-high cholesterol (437 mg/1,000 kcal) (milk-fat based) diets. The mice responded to increased dietary fat by increasing both HDL-C and apo A-I levels, with a greater increase in HDL-C levels. This was compatible with an increase in HDL size observed by nondenaturing gradient gel electrophoresis. Turnover studies with doubly labeled HDL showed that dietary fat both increase the transport rate (TR) and decreased the fractional catabolic rate of HDL cholesterol ester (CE) and apo A-I, with the largest effect on HDL CE TR. The latter suggested that dietary fat increases reverse cholesterol transport through the HDL pathway, perhaps as an adaptation to the metabolic load of a high fat diet. The increase in apo A-I TR by dietary fat was confirmed by experiments showing increased apo A-I secretion from primary hepatocytes isolated from animals on the high fat diet. The increased apo A-I production was not associated with any increase in hepatic or intestinal apo A-I mRNA, suggesting that the mechanism of the dietary fat effect was posttranscriptional, involving either increased translatability of the apo A-I mRNA or less intracellular apo A-I degradation. The dietary fat-induced decrease in HDL CE and apo A-I fractional catabolic rate may have been caused by the increase in HDL particle size, as was suggested by our previous studies in humans. In summary, a mouse model has been developed and experiments performed to better understand the paradoxical HDL-raising effect of a high fat diet.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473509      PMCID: PMC288145          DOI: 10.1172/JCI116375

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

Review 1.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

2.  Characterization of human high-density lipoproteins by gradient gel electrophoresis.

Authors:  P J Blanche; E L Gong; T M Forte; A V Nichols
Journal:  Biochim Biophys Acta       Date:  1981-09-24

3.  Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women.

Authors:  E A Brinton; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes.

Authors:  C E Sparks; J D Sparks; M Bolognino; A Salhanick; P S Strumph; J M Amatruda
Journal:  Metabolism       Date:  1986-12       Impact factor: 8.694

5.  Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion.

Authors:  R A Borchardt; R A Davis
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

6.  High density lipoprotein metabolism in man.

Authors:  C B Blum; R I Levy; S Eisenberg; M Hall; R H Goebel; M Berman
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

7.  Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters.

Authors:  T Chajek-Shaul; T Hayek; A Walsh; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

8.  Regulation of intestinal and hepatic apoprotein synthesis after chronic fat and cholesterol feeding.

Authors:  M F Go; G Schonfeld; B Pfleger; T G Cole; N L Sussman; D H Alpers
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

9.  High density lipoprotein metabolism in a rabbit model of hyperalphalipoproteinemia.

Authors:  D W Quig; D B Zilversmit
Journal:  Atherosclerosis       Date:  1989-03       Impact factor: 5.162

10.  Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia.

Authors:  E A Brinton; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more
  41 in total

1.  Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.

Authors:  P Holvoet; S Danloy; E Deridder; M Lox; H Bernar; A Dhoest; D Collen
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

2.  Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL.

Authors:  Marta Marchesi; Cinzia Parolini; Silvia Caligari; Donatella Gilio; Stefano Manzini; Marco Busnelli; Paola Cinquanta; Marina Camera; Marta Brambilla; Cesare R Sirtori; Giulia Chiesa
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

3.  Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene.

Authors:  S Naganawa; H N Ginsberg; R M Glickman; G S Ginsburg
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

4.  Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.

Authors:  Guoping Li; Antonio Hernandez-Ono; Rosanne M Crooke; Mark J Graham; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2011-03-01       Impact factor: 5.922

5.  Mice lacking ARV1 have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease.

Authors:  Christina Gallo-Ebert; Jamie Francisco; Hsing-Yin Liu; Riley Draper; Kinnari Modi; Michael D Hayward; Beverly K Jones; Olesia Buiakova; Virginia McDonough; Joseph T Nickels
Journal:  J Biol Chem       Date:  2018-02-28       Impact factor: 5.157

6.  Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets.

Authors:  Rong Wu; Wei Zhang; Bo Liu; Jing Gao; Xiao-Qiu Xiao; Feng Zhang; Hua-Mei Zhou; Xiao-Ling Wu; Xia Zhang
Journal:  Dig Dis Sci       Date:  2012-08-10       Impact factor: 3.199

7.  apo B gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesterol ester and apo A-I transport rates in heterozygotes.

Authors:  L S Huang; E Voyiaziakis; D F Markenson; K A Sokol; T Hayek; J L Breslow
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Authors:  L Berthou; N Duverger; F Emmanuel; S Langouët; J Auwerx; A Guillouzo; J C Fruchart; E Rubin; P Denèfle; B Staels; D Branellec
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

Authors:  Min He; Haoran Su; Weiwei Gao; Stina M Johansson; Qing Liu; Xiaoyan Wu; Jiayu Liao; Andrew A Young; Tamas Bartfai; Ming-Wei Wang
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

10.  Mild hypercholesterolemia blunts the proinflammatory and prothrombotic effects of hypertension on the cerebral microcirculation.

Authors:  Stephen F Rodrigues; Shantel A Vital; D Neil Granger
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-02       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.